Bliss GVS Pharma Ltd
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
- Market Cap ₹ 1,063 Cr.
- Current Price ₹ 102
- High / Low ₹ 150 / 75.4
- Stock P/E 14.0
- Book Value ₹ 94.4
- Dividend Yield 0.49 %
- ROCE 11.2 %
- ROE 7.88 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 1.08 times its book value
Cons
- The company has delivered a poor sales growth of 7.25% over past five years.
- Promoter holding is low: 35.0%
- Company has a low return on equity of 9.46% over last 3 years.
- Dividend payout has been low at 7.34% of profits over last 3 years
- Company has high debtors of 241 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
354 | 288 | 313 | 326 | 348 | 298 | 427 | 442 | 466 | 636 | 598 | 605 | |
253 | 222 | 227 | 230 | 247 | 209 | 331 | 342 | 374 | 527 | 508 | 498 | |
Operating Profit | 101 | 66 | 86 | 97 | 101 | 88 | 95 | 100 | 91 | 109 | 90 | 107 |
OPM % | 29% | 23% | 28% | 30% | 29% | 30% | 22% | 23% | 20% | 17% | 15% | 18% |
15 | 30 | 21 | 23 | 9 | 11 | 33 | 37 | 18 | 35 | 51 | -8 | |
Interest | 7 | 9 | 11 | 14 | 9 | 7 | 3 | 7 | 4 | 4 | 10 | 6 |
Depreciation | 4 | 4 | 5 | 6 | 6 | 6 | 6 | 9 | 14 | 14 | 15 | 24 |
Profit before tax | 105 | 82 | 91 | 100 | 95 | 87 | 120 | 122 | 91 | 126 | 116 | 70 |
Tax % | 46% | 34% | 34% | 35% | 38% | 34% | 38% | 24% | 26% | 27% | 26% | 28% |
57 | 54 | 60 | 66 | 59 | 57 | 74 | 92 | 68 | 93 | 85 | 51 | |
EPS in Rs | 5.50 | 5.23 | 5.82 | 6.36 | 5.73 | 5.53 | 7.22 | 8.95 | 6.54 | 8.94 | 8.21 | 4.84 |
Dividend Payout % | 13% | 10% | 12% | 8% | 10% | 18% | 14% | 6% | 8% | 6% | 6% | 10% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 7% |
3 Years: | 9% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | 3% |
5 Years: | 0% |
3 Years: | 4% |
TTM: | -11% |
Stock Price CAGR | |
---|---|
10 Years: | 8% |
5 Years: | -8% |
3 Years: | -2% |
1 Year: | 27% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 10% |
3 Years: | 9% |
Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 248 | 305 | 358 | 422 | 481 | 531 | 593 | 673 | 745 | 841 | 927 | 978 |
76 | 86 | 90 | 81 | 75 | 94 | 72 | 93 | 92 | 90 | 81 | 78 | |
122 | 85 | 97 | 71 | 99 | 59 | 61 | 79 | 98 | 139 | 122 | 87 | |
Total Liabilities | 456 | 486 | 555 | 585 | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,153 |
49 | 54 | 82 | 79 | 76 | 73 | 79 | 180 | 175 | 225 | 326 | 331 | |
CWIP | 1 | 4 | -0 | 2 | 2 | 0 | 43 | -0 | 2 | 22 | 3 | 8 |
Investments | 19 | 19 | 19 | 21 | 21 | 18 | 18 | 18 | 18 | 18 | 18 | 19 |
388 | 409 | 454 | 483 | 567 | 602 | 596 | 657 | 750 | 815 | 793 | 795 | |
Total Assets | 456 | 486 | 555 | 585 | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,153 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-52 | 65 | 15 | 60 | 38 | 23 | 48 | 63 | 67 | 114 | 44 | 126 | |
-27 | -24 | -19 | -15 | -29 | 16 | -68 | -60 | -62 | -92 | -13 | -110 | |
52 | -3 | -31 | -35 | -15 | -22 | 9 | -6 | -12 | -13 | -26 | -21 | |
Net Cash Flow | -27 | 38 | -35 | 10 | -6 | 17 | -11 | -3 | -6 | 9 | 5 | -4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 225 | 232 | 246 | 280 | 251 | 346 | 293 | 334 | 273 | 234 | 243 | 241 |
Inventory Days | 48 | 53 | 58 | 59 | 61 | 100 | 89 | 93 | 121 | 96 | 86 | 109 |
Days Payable | 181 | 147 | 130 | 94 | 139 | 88 | 50 | 86 | 96 | 89 | 88 | 66 |
Cash Conversion Cycle | 92 | 138 | 173 | 245 | 173 | 357 | 332 | 342 | 298 | 241 | 241 | 283 |
Working Capital Days | 143 | 163 | 216 | 263 | 400 | 553 | 367 | 401 | 367 | 294 | 323 | 313 |
ROCE % | 40% | 25% | 24% | 23% | 19% | 15% | 19% | 18% | 12% | 14% | 13% |
Documents
Announcements
- Closure of Trading Window 1d
-
Intimation Regarding The Appointment Of Additional Non-Executive Independent Director
22 Jun - Approval of shareholders in ensuing 39th Annual General Meeting and based on recommendation of the Nomination and Remuneration Committee, the Board of the Company through …
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
21 Jun - Disclosure pursuant to Regulation 30 of the SEBI LODR Regulations 2015 is enclosed.
-
Announcement under Regulation 30 (LODR)-Credit Rating
19 Jun - Read with Schedule III of the SEBI (LODR) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CSD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we would like to inform you …
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
10 Jun - The ESOP Allotment Committee of the Company at its meeting held on June 10, 2024, has approved the allotment of 1,45,000 equity shares of the …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio:
a) Pharma Products:[1]
Capsules, Creams/Gels/Ointments, Dry Powder for Injection and for Oral Suspension, Eye/Ear Drops, Effervescent tablets, Lotions, Injections, Liquid Preparations, Lozenges, Nasal Solutions, Oral Solids, Parenteral, etc.
b) Other Healthcare Products:[2]
Balm, Cream, Lotion, OTC products, Petroleum Jelly, Powder, Roll On
c) Therapeutics:[3]
Analgesic, Antacid, Anti-malarial, Anti-fungal, Anti-bacterial, Anti-biotic, Anti-inflammatory, Anti-diarrheic, anti-diabetic, etc.